Charles Schwab Investment Management Inc. Has $692,000 Holdings in Ocugen, Inc. (NASDAQ:OCGN)

Charles Schwab Investment Management Inc. lifted its stake in shares of Ocugen, Inc. (NASDAQ:OCGN) by 12.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 860,244 shares of the company’s stock after buying an additional 93,288 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.30% of Ocugen worth $692,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Barclays PLC grew its holdings in Ocugen by 104.3% in the third quarter. Barclays PLC now owns 581,087 shares of the company’s stock worth $577,000 after purchasing an additional 296,654 shares during the period. Rhumbline Advisers grew its stake in shares of Ocugen by 12.9% in the 4th quarter. Rhumbline Advisers now owns 324,475 shares of the company’s stock valued at $261,000 after buying an additional 37,034 shares during the period. State Street Corp grew its stake in shares of Ocugen by 7.1% in the 3rd quarter. State Street Corp now owns 15,824,517 shares of the company’s stock valued at $15,701,000 after buying an additional 1,047,896 shares during the period. SG Americas Securities LLC raised its stake in Ocugen by 72.7% during the 4th quarter. SG Americas Securities LLC now owns 152,176 shares of the company’s stock worth $123,000 after buying an additional 64,080 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Ocugen during the 4th quarter worth approximately $40,000. Institutional investors own 10.27% of the company’s stock.

Wall Street Analysts Forecast Growth

OCGN has been the subject of several recent research reports. Chardan Capital boosted their price objective on Ocugen from $6.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, March 6th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Ocugen in a research note on Thursday, March 6th.

Ocugen Price Performance

OCGN stock opened at $0.71 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The business has a 50-day simple moving average of $0.67 and a two-hundred day simple moving average of $0.83. The company has a market capitalization of $207.33 million, a P/E ratio of -3.94 and a beta of 3.88. Ocugen, Inc. has a 52-week low of $0.52 and a 52-week high of $2.08.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. Research analysts expect that Ocugen, Inc. will post -0.2 EPS for the current fiscal year.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.